Recombinant Antibodies: Covagen AG presents the Fynomer technology

Tid 14 Juni 2010 – 18 Juni 2010

Plats The Crowne Plaza Berlin City Centre, Germany

Speaker: Dr. Simon Brack, Head of Lead Discovery, Covagen AG, Zürich, Switzerland Topic: Fynomers Neutralizing IL-17A: Making Use of Fc fusion protein We will present the versatility and broad applicability of the Fynomer technology. As an example, the isolation and characterization of high-affinity Fynomers capable of neutralizing IL-17 will be shown. Furthermore, engineered Fynomer-Fc fusion proteins having appropriate physico-chemical and in vivo half-life properties are attractive drug candidates for pre-clinical and clinical development. For more info about the event please visit www.informaglobalevents.com/event/antibodies

Kategorier

  • biosensor
  • attana
  • attana a200
  • fynomer
  • drug candidate

Relaterat innehåll

  • Characterisation of complex lectin-cell kinetics (Attana Application Example)

    Attana Cell 200 - Label free, real time kinetics on cells, exploring biology on a new level!
     
    In the development process of new pharmaceutical compounds, kinetic experiments provide insights
    into potential drug candidates while also defining lead targets. In this application example we demonstrate the ability of the Attana Cell™ 200 to provide a complete and highly relevant analysis of a

Relaterade event